{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:28:44Z","timestamp":1791354524213,"version":"4.3.1"},"reference-count":53,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4254\/wjh.v8.i3.139","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T01:47:17Z","timestamp":1453340837000},"page":"139","source":"Crossref","is-referenced-by-count":58,"title":["Advances in hepatitis C therapy: What is the current state - what come's next?"],"prefix":"10.4254","volume":"8","author":[{"given":"Steffen","family":"Zopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03432.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02188.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371006"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.032"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.012"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307498"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.044"},{"key":"ref21","unstructured":"Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, Younossi Z, Lawitz E. O046: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60 Suppl 1:220a-220a."},{"key":"ref22","unstructured":"Jensen DM, O’Leary JG, Pockros PJ, Sherman KE, Kwo PY, Mailliard ME, Kowdley KV, Muir AJ, Dickson RC, Ramani A. O045: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. Hepatology 2014;60 Suppl 1:219a-220a."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30168-9"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30158-6"},{"key":"ref25","unstructured":"Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R, McPhee F, Hughes E, Noviello S, Swenson E. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: phase 3 ALLY-1 study. J Viral Hepatitis 2015;22:30-31."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1401726"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gane EJ, Hyland RH, An D, Svarovskaia ES, Pang PS, Symonds WT, McHutchison JG, Stedman CA. High Efficacy of LDV\/SOF Regimens for 12 Weeks for Patients with HCV Genotype 3 or 6 Infection. Hepatology 2014;60:1274a-1275a.","DOI":"10.1016\/S0168-8278(13)60016-1"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"ref38","unstructured":"Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal NH. O239: Ledipasvir\/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2014;60 Suppl 1:320a-321a."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30147-1"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"ref45","unstructured":"Ng T, Pilot-Matias T, Lu LJ, Reisch T, Dekhtyar T, Krishnan P, Beyer J, Tripathi R, Pithawalla RB, Asatryan A. P1946: A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 with High Barriers to Resistance. Hepatology 2014;60 Suppl 1:1142a-1142a."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30013-1"},{"key":"ref47","unstructured":"Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han LL, Doehle B. O197: High Efficacy of Treatment with Sofosbuvir GS-5816 \/- Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection. Hepatology 2014;60 Suppl 1:297a-298a."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30160-4"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61228-9"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61382-9"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i3\/139.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T02:10:39Z","timestamp":1654135839000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i3\/139.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v8.i3.139","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}